The Korean Journal of Pain

  • 제35권1호
  • /
  • Pages.4-13
  • /
  • 2022
  • /
  • 2005-9159(pISSN)
  • /
  • 2093-0569(eISSN)
대한통증학회 (The Korean Pain Society)
권호 표지
DOI QR코드

DOI QR Code

The evolving classifications and epidemiological challenges surrounding chronic migraine and medication overuse headache: a review

  • 투고 : 2021.07.16
  • 심사 : 2021.10.15
  • 발행 : 2022.01.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Changes in diagnostic criteria, for example, the various International Classification of Headache Disorders criteria, would lead to changes in the outcomes of epidemiological studies. International Classification of Headache Disorders-1 was based mainly on expert opinion, yet most of the diagnostic criteria were reliable and valid, but it did not include chronic migraine. In its second version, the classification introduced chronic migraine, but this diagnosis resembled more a high-frequency migraine rather than the actual migraine transformation process. It also introduced medication overuse headache, but it necessitated analgesic withdrawal and subsequent headache improvement to be diagnosed as such. Hence patients having medication overuse headache could only be diagnosed in retrospect, which was an awkward situation. Such restrictive criteria for chronic migraine and medication overuse headache omitted a high proportion of patients. International Classification of Headache Disorders-3 allows a diagnosis of medication overuse headache due to combination analgesics if taken for at least 10 days per month for more than three months. Hence the prevalence rate of medication overuse headache and chronic migraine can increase compared to the previous version of the headache classification. Different criteria have been used across studies to identify chronic migraine and medication overuse headache, and therefore the information acquired from previous studies using earlier criteria becomes uncertain. Hence much epidemiological research would need to be interpreted cautiously or repeated with the most updated criteria, since the subjects in studies that apply the latest criteria may be phenotypically different from those in older studies.

키워드

과제정보

This article was originally submitted as part of the MSc in the Clinical Management of Pain at the University of Edinburgh, Edinburgh, UK.

참고문헌

  1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789-858. https://doi.org/10.1016/s0140-6736(18)32279-7
  2. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954-76. https://doi.org/10.1016/S1474-4422(18)30322-3
  3. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain 2015; 16: 58. https://doi.org/10.1186/s10194-015-0544-2
  4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211-59. https://doi.org/10.1016/S0140-6736(17)32154-2
  5. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377: 2113-22. https://doi.org/10.1056/NEJMoa1709038
  6. Giamberardino MA, Affaitati G, Curto M, Negro A, Costantini R, Martelletti P. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med 2016; 11: 1045-57. https://doi.org/10.1007/s11739-016-1489-4
  7. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barre J, Katsarava Z, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012; 19: 703-11. https://doi.org/10.1111/j.1468-1331.2011.03612.x
  8. Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lanteri-Minet M, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014; 15: 31. https://doi.org/10.1186/1129-2377-15-31
  9. Steiner TJ, Stovner LJ, Al Jumah M, Birbeck GL, Gururaj G, Jensen R, et al. Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. J Headache Pain 2013; 14: 87. https://doi.org/10.1186/1129-2377-14-87
  10. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8 Suppl 7: 1-96. https://doi.org/10.1046/j.1468-2982.1988.0801001.x
  11. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1: 9-160. https://doi.org/10.1111/j.1468-2982.2003.00824.x
  12. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629-808. https://doi.org/10.1177/0333102413485658
  13. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1-211.
  14. Olesen J, Steiner TJ. The international classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry 2004; 75: 808-11. https://doi.org/10.1136/jnnp.2003.031286
  15. Silberstein SD, Lipton RB, Solomon S, Mathew NT. Classification of daily and near-daily headaches: proposed revisions to the IHS criteria. Headache 1994; 34: 1-7.
  16. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47: 871-5. https://doi.org/10.1212/WNL.47.4.871
  17. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6. https://doi.org/10.1111/j.1468-2982.2006.01172.x
  18. Manzoni GC, Grisendi I, Torelli P. ICHD-3: what changes do we need regarding migraine? Curr Pain Headache Rep 2011; 15: 170-6. https://doi.org/10.1007/s11916-011-0188-0
  19. Katsarava Z, Manack A, Yoon MS, Obermann M, Becker H, Dommes P, et al. Chronic migraine: classification and comparisons. Cephalalgia 2011; 31: 520-9. https://doi.org/10.1177/0333102410383590
  20. Olesen J. International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. Cephalalgia 2006; 26: 1409-10. https://doi.org/10.1111/j.1468-2982.2006.01214.x
  21. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. The International Classification of Headache Disorders revised criteria for chronic migraine-field testing in a headache specialty clinic. Cephalalgia 2007; 27: 230-4. https://doi.org/10.1111/j.1468-2982.2006.01274.x
  22. Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Field testing alternative criteria for chronic migraine. Cephalalgia 2006; 26: 477-82. https://doi.org/10.1111/j.1468-2982.2006.01128.x
  23. Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, et al. Prevalence of chronic migraine and medication overuse headache in Germany--the German DMKG headache study. Cephalalgia 2010; 30: 207-13. https://doi.org/10.1111/j.1468-2982.2009.01906.x
  24. Manzoni GC, Bonavita V, Bussone G, Cortelli P, Narbone MC, Cevoli S, et al. Chronic migraine classification: current knowledge and future perspectives. J Headache Pain 2011; 12: 585-92. https://doi.org/10.1007/s10194-011-0393-6
  25. Jiang H, Deng Y, Zhang Y, Jin J, Kong X, Zhu Q, et al. Field testing of the ICHD-3β and expert opinion criteria for chronic migraine. J Headache Pain 2016; 17: 85. https://doi.org/10.1186/s10194-016-0678-x
  26. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 2016; 12: 455-64. https://doi.org/10.1038/nrneurol.2016.93
  27. Russell MB. Epidemiology and management of medication-overuse headache in the general population. Neurol Sci 2019; 40(Suppl 1): 23-6. https://doi.org/10.1007/s10072-019-03812-8
  28. Goadsby PJ, Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache 2008; 48: 1399-405. https://doi.org/10.1111/j.1526-4610.2008.01274.x
  29. Torres-Ferrus M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia 2017; 37: 104-13. https://doi.org/10.1177/0333102416636055
  30. Manzoni GC, Torelli P. Chronic headaches: a clinician's experience of ICHD-3 beta. Neurol Sci 2015; 36 Suppl 1: 51-5. https://doi.org/10.1007/s10072-015-2142-0
  31. Schwedt TJ, Chong CD. Medication overuse headache: pathophysiological insights from structural and functional brain MRI research. Headache 2017; 57: 1173-8. https://doi.org/10.1111/head.13037
  32. Martelletti P. The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. J Headache Pain 2018; 19: 2. https://doi.org/10.1186/s10194-017-0830-2
  33. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545-602. https://doi.org/10.1016/S0140-6736(16)31678-6
  34. Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 2018; 19: 50. https://doi.org/10.1186/s10194-018-0875-x
  35. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803. https://doi.org/10.1177/0333102410364676
  36. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-14. https://doi.org/10.1177/0333102410364677
  37. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-36. https://doi.org/10.1111/j.1526-4610.2010.01678.x
  38. National Institute for Health and Care Excellence (NICE). Botulinum toxin type A for the prevention of headaches in adults with chronic migraine [Internet]. London: NICE; 2012. Available at: https://www.nice.org.uk/guidance/ta260/resources/botulinum-toxin-typea-for-the-prevention-of-headaches-in-adults-with-chronic-migrainepdf-82600545273541.
  39. Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia 2014; 34: 409-25. https://doi.org/10.1177/0333102413512033
  40. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-9. https://doi.org/10.1001/jama.1992.03480010072027
  41. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-57. https://doi.org/10.1046/j.1526-4610.2001.041007646.x
  42. Winter AC, Berger K, Buring JE, Kurth T. Associations of socioeconomic status with migraine and non-migraine headache. Cephalalgia 2012; 32: 159-70. https://doi.org/10.1177/0333102411430854
  43. Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-6. https://doi.org/10.1046/j.1526-4610.1999.3903190.x
  44. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48: 1157-68. https://doi.org/10.1111/j.1526-4610.2008.01217.x
  45. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52: 1456-70. https://doi.org/10.1111/j.1526-4610.2012.02223.x
  46. Steiner TJ, Gururaj G, Andree C, Katsarava Z, Ayzenberg I, Yu SY, et al. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain 2014; 15: 3. https://doi.org/10.1186/1129-2377-15-3
  47. Streel S, Donneau AF, Hoge A, Albert A, Schoenen J, Guillaume M. One-year prevalence of migraine using a validated extended French version of the ID MigraineTM: a Belgian population-based study. Rev Neurol (Paris) 2015; 171: 707-14. https://doi.org/10.1016/j.neurol.2015.04.009
  48. Streel S, Donneau AF, Dardenne N, Hoge A, Bruyere O, Albert A, et al. Validation of an extended French version of ID MigraineTM as a migraine-screening tool. Cephalalgia 2015; 35: 437-42. https://doi.org/10.1177/0333102414544910
  49. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 2003; 61: 375-82. https://doi.org/10.1212/01.WNL.0000078940.53438.83
  50. da Silva A Jr, Costa EC, Gomes JB, Leite FM, Gomez RS, Vasconcelos LP, et al. Chronic headache and comorbidities: a two-phase, population-based, cross-sectional study. Headache 2010; 50: 1306-12. https://doi.org/10.1111/j.1526-4610.2010.01620.x
  51. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart JA. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag Health Studies. Pain 2012; 153: 56-61. https://doi.org/10.1016/j.pain.2011.08.018
  52. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743-800. https://doi.org/10.1016/S0140-6736(15)60692-4
  53. Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 2017; 18: 101. https://doi.org/10.1186/s10194-017-0787-1
  54. Steiner TJ, Stovner LJ. Societal impact of headache: burden, costs and response. Cham, Springer. 2019, pp 83-104.